Lung cancer is a core area of expertise for Worldwide Clinical Trials. We support lung cancer programs from Phase I development through global registrational studies across biomarker-defined patient populations, targeted therapies, immunotherapies, ADCs, and other emerging treatment approaches.
Successfully executing lung cancer trials requires expertise in biomarker-driven patient identification and enrollment, molecular testing strategies, evolving standards of care, and complex trial designs in a competitive recruitment landscape.
Explore our fact sheet to see what sets our lung cancer program apart, including:
- A dedicated oncology business unit with an average of 11+ years of oncology experience across key roles and an industry-leading 90%+ retention rate
- A global footprint spanning 60+ early and late phase studies with 8,200+ patients across N.A., E.U., APAC, LATAM, and MENA
- Site experience across 455+ investigative sites in 32 countries, covering NSCLC and SCLC
- Expertise in next-generation drug modalities, including ADCs, multi/bi-specific antibodies, cell therapies/CAR T, and checkpoint, kinase, and small molecule inhibitors
- Flexible solutions and best-in-class technologies powered by a data-centric approach with visual analytics and clinical science
